Lipocine Piotroski F Score

LPCN -  USA Stock  

USD 1.14  0.02  1.79%

This module uses fundamental data of Lipocine to approximate its Piotroski F score. Lipocine F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Lipocine. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Lipocine financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Additionally, see Lipocine Altman Z Score, Lipocine Correlation, Lipocine Valuation, as well as analyze Lipocine Alpha and Beta and Lipocine Hype Analysis.

Lipocine Piotroski F Score 

 
Refresh
Lipocine Total Debt is quite stable at the moment as compared to the past year. The company's current value of Total Debt is estimated at 6.17 Million. Debt Non Current is expected to rise to about 3 M this year, although the value of Debt Current will most likely fall to about 3 M. Lipocine Current Ratio is quite stable at the moment as compared to the past year. The company's current value of Current Ratio is estimated at 3.95. Sales per Share is expected to rise to 0.005542 this year, although the value of Cash Flow Per Share will most likely fall to (0.30) .
At this time, it appears that Lipocine's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
1
Current Return On Assets
Negative
2
Change in Return on Assets
Decreased
3
Cash Flow Return on Assets
Negative
4
Current Quality of Earnings (accrual)
Improving
5
Asset Turnover Growth
Increase
6
Current Ratio Change
Increase
7
Long Term Debt Over Assets Change
Higher Leverage
8
Change In Outstending Shares
Increase
9
Change in Gross Margin
No Change

Lipocine Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Lipocine is to make sure Lipocine is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Lipocine's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Lipocine's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares60.1 M55.7 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted60.1 M55.7 M
Significantly Up
Increasing
Slightly volatile
Total Assets27.4 M25.4 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities8.1 M10 M
Significantly Down
Increasing
Slightly volatile
Current Assets27.4 M25.3 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities5.2 M6.6 M
Significantly Down
Increasing
Slightly volatile
Total Debt6.2 M5.6 M
Significantly Up
Decreasing
Slightly volatile
Return on Average Assets(0.91)(0.887)
Fairly Down
Decreasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Asset Turnover0.00740.0072
Fairly Up
Decreasing
Slightly volatile

Lipocine F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Lipocine's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Lipocine in a much-optimized way.

About Lipocine Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

0.28Share
Lipocine Book Value per Share is quite stable at the moment as compared to the past year. The company's current value of Book Value per Share is estimated at 0.28

Lipocine Current Valuation Drivers

We derive many important indicators used in calculating different scores of Lipocine from analyzing Lipocine's financial statements. These drivers represent accounts that assess Lipocine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lipocine's important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Net Income Per Employee(1.35 M)(1.5 M)(1.17 M)(1.08 M)(1.25 M)(1.34 M)
Average Assets32.25 M26.71 M25.13 M19.92 M23.65 M27.14 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(18.94 M)(20.95 M)(11.64 M)(12.22 M)(20.57 M)(22.2 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(18.94 M)(20.95 M)(11.64 M)(12.22 M)(20.57 M)(22.2 M)
Earnings before Tax(18.97 M)(20.98 M)(11.66 M)(13.01 M)(20.96 M)(21.52 M)
Average Equity30.14 M23.19 M12.94 M9.05 M12.37 M15.1 M
Enterprise Value62.49 M63.65 M28.3 M6.05 M77.75 M69.36 M
Free Cash Flow(18.34 M)(16.7 M)(12.08 M)(11.67 M)(15.3 M)(16.51 M)
Invested Capital20.46 M15.77 M13.54 M7.11 M142.07 K145.81 K
Invested Capital Average20.95 M14.18 M21.61 M11.44 M4.36 M4.47 M
Market Capitalization67.2 M72.92 M27.9 M9.78 M89.33 M81.84 M
Tangible Asset Value27.34 M25.33 M20.85 M19.66 M25.35 M27.45 M
Working Capital25.88 M18.87 M16.32 M14.67 M18.75 M22.16 M

About Lipocine Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lipocine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lipocine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lipocine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. Lipocine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.

Lipocine Investors Sentiment

The influence of Lipocine's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Lipocine. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Lipocine Implied Volatility

    
  278.18  
Lipocine's implied volatility exposes the market's sentiment of Lipocine stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Lipocine's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Lipocine stock will not fluctuate a lot when Lipocine's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lipocine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lipocine's short interest history, or implied volatility extrapolated from Lipocine options trading.

Current Sentiment - LPCN

Lipocine Investor Sentiment

Most of Macroaxis users are now bullish on Lipocine. What is your trading attitude regarding investing in Lipocine? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Lipocine using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Lipocine Altman Z Score, Lipocine Correlation, Lipocine Valuation, as well as analyze Lipocine Alpha and Beta and Lipocine Hype Analysis. Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Lipocine Stock analysis

When running Lipocine price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine Lipocine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.